ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1706 • ACR Convergence 2023

    Autoreactive B Cell Responses Are Enriched in Early-onset Oligoarticular Juvenile Idiopathic Arthritis

    Claudia Harris1, Maria Taylor2, Ki Pui Lam2, Indu Raman3, Chengsong Zhu3, Pui Lee1, Peter Nigrovic4, Erin Janssen5, Jing Cui6 and Lauren Henderson4, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Division of Immunology, Boston Children’s Hospital, Boston, MA, 3Department of Immunology, Microarray & Immune Phenotyping Core Facility, University of Texas, Southwestern Medical Center, Dallas, TX, 4Boston Children's Hospital, Boston, MA, 5Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: A subset of children with oligoarticular juvenile idiopathic arthritis (oligo JIA) who are anti-nuclear antibody (ANA) positive are known to have dysregulated T cell-B…
  • Abstract Number: 2001 • ACR Convergence 2023

    Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis

    Guy Katz1, Aubree McMahon1, Grace McMahon1, Isha Jha1, Marcy Bolster2, Ana Fernandes1, Zachary Wallace3, Cory Perugino1, John Stone4 and Yasmin Hernandez-Barco1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Concord, MA, 3Massachusetts General Hospital, Newton, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA

    Background/Purpose: Metabolic bone disease (MBD), including osteopenia and osteoporosis, is common in patients with inflammatory disorders, due to disease factors and glucocorticoid (GC) use, and…
  • Abstract Number: 1999 • ACR Convergence 2023

    One-year Incidence of Clinical Fragility Fractures After Implementing an Osteoporosis Care Protocol in Patients Eligible for Liver Transplantation

    Cristina Rodríguez-Alvear1, Mª Carmen López-González2, Elisabet Perea-Martínez3, Antonio Avilés-Hernández3, Irene Calabuig-Sais1, Maria-Luisa Peral-Garrido4, Pilar Bernabeu-Gonzálvez3, Agustín Martínez-Sanchís1, Joaquim Esteve-Vives3, PALOMA VELA5, Cayetano Miralles Maciá3, Vega Jovani6 and Mariano Andrés1, 1Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 2General University Hospital Dr. Balmis, Alacante, Spain, 3General University Hospital Dr. Balmis, Alicante, Spain, 4Vinalopó University Hospital, Novelda, Spain, 5Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 6Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain

    Background/Purpose: In solid organ transplantation, liver transplants are among those most frequently associated with the development of low bone mass, which occurs in up to…
  • Abstract Number: 2002 • ACR Convergence 2023

    Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures

    Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Yamei Wang4, Leny Pearman4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Boston, MA, 5University of Liège, Liège, Belgium

    Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…
  • Abstract Number: 1742 • ACR Convergence 2023

    Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA

    Rachna Talluri1, Sudeshna Sen2, Timothy Wilson3, Adam Savage4, Mark Gillespie4, Tom Bumol4, Marie Feser1, Jill Norri5, Michael Holer1, kevin Deane1, Paul Thompson2 and Kristen Demoruelle1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Massachusetts Chan Medical School, Worcester, MA, 3Thomas Jefferson University, Philadelphia, PA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Denver, CO

    Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
  • Abstract Number: 1740 • ACR Convergence 2023

    Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers

    Arkaitz Mucientes1, Martín-Núñez Gracia María2, José Lisbona-Montañez3, Patricia Ruiz-Limon4, Rocío Redondo-Rodríguez5, SARA MANRIQUE6, Inmaculada Ureña5, Laura Cano-García5, Isabel Moreno-Indias1, Natalia Mena Vazquez7 and Antonio Fernandez-Nebro8, 1IBIMA Plataforma BIONAND, Málaga, Spain, 2Universidad de Málaga, Departamento de Medicina y Dermatología, Málaga, Spain, 3Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, 4IBIMA Plataforma BIONAND, Cordoba, Spain, 5Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, 6Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 7IBIMA, Málaga, Spain, 8Hospital Regional Universitario de Málaga, Malaga, Spain

    Background/Purpose: The etiology of rheumatoid arthritis (RA) is not fully understood. It is accepted that RA results from the interplay of genetic and environmental factors.…
  • Abstract Number: 1670 • ACR Convergence 2023

    Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae

    CAMILA CAETANO1, Tamiris Azamor1, Nikki M. Meyer1, Cassandra Calabrese2, Leonard Calabrese2, Nicolas Piuzzi3, M. Elaine Husni2, Suan-Sin Foo1 and Weiqiang Chen1, 1Cleveland Clinic / Infection Biology Program, Global Center for Pathogen Research and Human Health, Lerner Research Institute, Cleveland, OH, 2Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, 3Cleveland Clinic / Department of Orthopedic Surgery, Cleveland, OH

    Background/Purpose: Patients with underlying immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have a higher susceptibility to severe COVID19…
  • Abstract Number: 1748 • ACR Convergence 2023

    Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies

    S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
  • Abstract Number: 1997 • ACR Convergence 2023

    A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis

    Richard Eastell1, Bente Langdahl2, Yoon-Sok Chung3, Rafal Plebanski4, Edward Czerwinski5, Eva Dokoupilova6, Jerzy Supronik7, Jan Rosa8, Anna Rowińska-Osuch9, Ki-Hyun Baek10, Audrone Urboniene11, Sohui Ahn12, Younghee Rho12 and Jisuk Ban12, 1University of Sheffield, Sheffield, United Kingdom, 2Aarhus University Hospital, Aarhus, Denmark, 3Ajou University Hospital, Suwon, South Korea, 4Klinika Zdrowej Kosci, Łódź, Poland, 5Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, 6Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, 7OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, 8Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, 9ETG Warszawa, Warszawa, Poland, 10Yeouido ST. Mary's Hospital, Seoul, South Korea, 11JSC Saules seimos medicinos centras, Kaunas, Lithuania, 12Samsung Bioepis, Incheon, South Korea

    Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
  • Abstract Number: 1654 • ACR Convergence 2023

    A Peer Health Coached Resilience-Based Energy Management Program Was Effective in Improving Fatigue and Other Outcomes in People with Systemic Sclerosis: Results of a Randomized Controlled Trial

    Susan Murphy1, Yen Chen2, Mary Alore2, Sheri Hicks2, Adam Pape2, Afton Hassett2, Anna Kratz2, Daniel Whibley2, Alexandra Harper3, Suiyuan Huang2, Gina Jay2, Shannen Bolde2 and Dinesh Khanna2, 1University of Michigan, Plymouth, MI, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Ypsilanti Charter Twp, MI

    Background/Purpose: Systemic sclerosis (SSc), a rare autoimmune condition, has a high chronic symptom burden that can have dramatic, life-altering effects on function and quality of…
  • Abstract Number: 1663 • ACR Convergence 2023

    Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells

    Kimberly Lakin1, Robert Spiera2, Yaxia Zhang1, David Oliver1, Aliza Bloostein1, Hiranmayi Ravichandran3, Niroshana Anandasabapathy3, Franck Barrat1, Jessica Gordon1 and Dana Orange4, 1Hospital for Special Surgery, New York, NY, 2Hosptial for Special Surgery, New York, NY, 3Weill Cornell Medical College, New York, NY, 4The Rockefeller University, New York, NY

    Background/Purpose: We have previously shown that skin fibroblast activation is related to clinical severity and resolves with improvement in diffuse systemic sclerosis (dcSSc). The immune…
  • Abstract Number: 1042 • ACR Convergence 2023

    B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis

    Shinji Watanabe1, Keina Yomono2, Shintaro Yamamoto1, Mikito Suzuki3, Takahisa Gono4 and Masataka Kuwana4, 1Nippon Medical School, Tokyo, Japan, 2Nippon Medical School University, Tokyo, Japan, 3Nippon Medical School Hospital, Tokyo, Japan, 4Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Lung ultrasound (LUS) is a non-invasive imaging tool to evaluate distribution and severity of interstitial lung disease (ILD). Utility of LUS has been examined…
  • Abstract Number: 1462 • ACR Convergence 2023

    Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Sara garcia Perez1, Jose-Maria Pego-Reigosa2, Irene Altabás González1, Norman Jiménez3, Victor Del campo Perez4, JULIA MARTINEZ BARRIO5, Maria Galindo-Izquierdo6, Jaime Calvo- Alén7, Esther Uriarte Isacelaya8, Eva Tomero Muriel9, Mercedes Freire González10, Victor Martinez-Taboada11, Paloma Vela12, Antonio Fernandez-Nebro13, Alejandro Olivé-Marqués14, Javier Narvaez15, Raúl Menor-Almagro16, Gregorio Santos Soler17, José Ángel Hernández Beriain18, Javier Manero ruiz19, Elena Aurrecoechea Aguinaga20, Oihane Ibarguengoitia-Barrena21, Carlos Montilla-Morales22, Gema Bonilla23, Vicente Torrente-Segarra24, Ana Paula Cacheda25, Maria J. García-Villanueva26, Clara Moriano Morales27, Concepción Fito Manteca28, Cristina Bohórquez29, Nuria Lozano Rivas30 and Iñigo Rúa-Figueroa31, 1Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, 2Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 3IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, 4Department of Epidemiology, University Hospital of Vigo, IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, 5Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 6Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, 7Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 8Rheumatology, University Hospital of Donosti, San Sebastián, Spain, 9Rheumatology, Hospital La Princesa, Madrid, Spain, 10Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 11Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, 12Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, 13Hospital Regional Universitario de Málaga, Malaga, Spain, 14Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 15Hospital Universitario de Bellvitge, Barcelona, Spain, 16Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 17Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, 18Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 19Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, 20Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, 21Galdakao-Usansolo University Hospital, Bilbao, Spain, 22Rheumatology, University Hospital of Salamanca, Salamanca, Spain, 23Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 24Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, 25Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, 26Hospital Ramón y Cajal, Madrid, Spain, 27Rheumatology, Hospital Universitario de León, León, Spain, 28Department of Rheumatology, University Hospital of Navarra, Pamplona, Spain, 29Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, 30Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 31Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain

    Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…
  • Abstract Number: 1474 • ACR Convergence 2023

    Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)

    Vineeta Shobha1, Liza Rajasekhar2, Sandra Manuel3, Nayana V3, Ranjan Gupta4, Bidyut Das5, Parasar Ghosh6, Chengappa Kavadichanda7, Ashish J Mathew8, Manish Rathi9, Avinash Jain10, Sumithra Selvam3 and Amita Aggarwal11, 1St. John's National Academy of Health Science, Bangalore, India, 2Nizam's Institute of Medical Sciences, Madhapur, India, 3St. John's Research Institute, Bangalore, India, 4All India Institute of Medical Sciences, New Delhi, India, 5SCB medical college, Cuttack, India, 6Govt of West Bengal, Kolkata, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 8Christian Medical College, Vellore, India, 9Postgraduate Institute of Medical education and Research, Chandigarh, India, 10SMS Medical College, Lucknow, India, 11Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

    Background/Purpose: Among the cutaneous manifestations of SLE, critical peripheral ischemia (CPI) including digital infarcts and gangrene are considered rare, gangrene occurring only in about 0.2%…
  • Abstract Number: 1052 • ACR Convergence 2023

    Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking

    Sokratis Apostolidis1, Kyra Sacksith1, Bria Fulmer1, Zoe Quandt2, Mark Anderson2, Terri Laufer3 and E. John Wherry1, 1University of Pennsylvania, Philadelphia, PA, 2University of California San Francisco, San Franscisco, CA, 3University of Pennsylvania, Philadlephia, PA

    Background/Purpose: The use of anti-PD-1 (aPD-1) immunotherapy has seen significant success in clinical practice, corresponding with a continued rise in clinical indications for multiple cancer…
  • « Previous Page
  • 1
  • …
  • 427
  • 428
  • 429
  • 430
  • 431
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology